Dr. Alexander Birbrair is now working as a professor at Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil. He has the membership in American Heart Association, Western NC Chapter of the Society for Neuroscience and International Society for Stem Cell Research.

He has more than fifteen peer reviewed papers and others are on pipeline. Dr. Alexander Birbrair's research interest includes Stem Cell, Oncology, Therapeutics etc.

Sergey Suchkov has completed his graduation from Astrakhan State Medical University and awarded with MD, PhD at the I.M. Sechenov Moscow Medical Academy and Doctorship degree at the National Institute of Immunology, Russia. He was a Senior Researcher, Koltzov Institute of Developmental Biology and was the Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. Currently he is a Chair, Department for Personalized and Translational Medicine, I.M. Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); and PMC (Personalized Medicine Coalition), USA.

Immunochemical characteristics of three novel reina-specific antigens in humans and some mammals, Serology in ophthalmic oncology - findings and outlook for the future, Catalytic antibodies in immune-mediated disor-ders, Clinical and immune-mediated syndrome (CAIMS) in clinical practice: features and strate-gies in immune and molecular diagnostics

Sergey Suchkov has completed his graduation from Astrakhan State Medical University and awarded with MD, PhD at the I.M. Sechenov Moscow Medical Academy and Doctorship degree at the National Institute of Immunology, Russia. He was a Senior Researcher, Koltzov Institute of Developmental Biology and was the Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. Currently he is a Chair, Department for Personalized and Translational Medicine, I.M. Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); and PMC (Personalized Medicine Coalition), USA.

Immunochemical characteristics of three novel reina-specific antigens in humans and some mammals, Serology in ophthalmic oncology - findings and outlook for the future, Catalytic antibodies in immune-mediated disor-ders, Clinical and immune-mediated syndrome (CAIMS) in clinical practice: features and strate-gies in immune and molecular diagnostics

Sergey Suchkov has completed his graduation from Astrakhan State Medical University and awarded with MD, PhD at the I.M. Sechenov Moscow Medical Academy and Doctorship degree at the National Institute of Immunology, Russia. He was a Senior Researcher, Koltzov Institute of Developmental Biology and was the Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. Currently he is a Chair, Department for Personalized and Translational Medicine, I.M. Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); and PMC (Personalized Medicine Coalition), USA.

Immunochemical characteristics of three novel reina-specific antigens in humans and some mammals, Serology in ophthalmic oncology - findings and outlook for the future, Catalytic antibodies in immune-mediated disor-ders, Clinical and immune-mediated syndrome (CAIMS) in clinical practice: features and strate-gies in immune and molecular diagnostics

Jonathan Schwartz has over 30 years doing international business consulting for emerging medical technologies and has been focused on stem cell technologies and regenerative medicine for the past six years. He currently is the Managing Director of the Regenerative Cellular Institute in the United States and does business consulting for several companies globally, including, Mystem, Bioquark, WinCell, StemCells21, IntellihealthPlus, Al Mediq, Glo PRP, WeHealPlus, and Arpwave. He has previously worked in many capacities with Spacelabs Medical, GE Healthcare, Intellicell Biosciences, Coloplast, and Smith and Nephew. He has degrees from Queens College, Almeda University and NYU Medical School.

His research interests are stem cells, regenerative medicine, cell therapy. clinical trails.

Dr. Alexander Birbrair is now working as a professor at Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil. He has the membership in American Heart Association, Western NC Chapter of the Society for Neuroscience and International Society for Stem Cell Research. He has more than fifteen peer reviewed papers and others are on pipeline.

Dr. Alexander Birbrair's research interest includes Stem Cell, Oncology, Therapeutics etc.

A/Professor Kuldip Sidhu had training with Prof James Thompson, Wisconsin USA (2000) who produced the first human embryonic stem cells in 1998 and Prof Shinya Yamanaka (2007-12), the Noble Laureate who developed iPSC technology and published data in Nature Biotechnology His research focus is on neural stem cells derived from both the embryonic and non-embryonic sources for developing future cell therapies for various neurodegenerative diseases, like Alzheimer’s, Parkinson’s and other neuronal diseases.

His research focus is on neural stem cells derived from both the embryonic and non-embryonic sources for developing future cell therapies for various neurodegenerative diseases, like Alzheimer’s, Parkinson’s and other neuronal diseases. His lab was first to produce two hESC lines, Endeavour (E) 1&2 from Australia and E2 is listed on NIH registry USA for distribution and several iPSC clones from Alzheimer’s patients for disease modelling. He is an author of two book, fifteen book chapters and 170 papers including abstracts.